A major new study has an urgent message for people with type 2 diabetes: stopping a popular class of medication could have serious consequences. The research links discontinuation of GLP-1 drugs with a nearly doubled risk of heart attack or stroke.
The Alarming Findings
A recent
study published in The Lancet Regional Health - Europe has shed light on a critical issue for patients managing type 2 diabetes. Researchers analyzed data from over 80,000 individuals and found that those who stopped taking a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists had a significantly higher risk of major cardiovascular events. Specifically, the combined risk of a non-fatal heart attack, non-fatal stroke, or death from any cause was approximately double for those who discontinued the medication compared to those who continued it. This translated to about four major events per 100 people per year in the group that stopped, versus two events per 100 people in the group that stayed on the treatment. The increased risk was even more pronounced in individuals with obesity.
Understanding GLP-1 Drugs
GLP-1 receptor agonists are a modern class of medications that have become vital in treating type 2 diabetes. They work by mimicking a natural hormone that helps regulate blood sugar, and they also have the benefit of helping with weight loss by curbing appetite. Beyond blood sugar control, large-scale clinical trials have proven that these drugs offer powerful protection for the heart and kidneys. Their ability to reduce the risk of major adverse cardiovascular events is a key reason they are prescribed. This protective effect appears to be significant, but the new study suggests that the benefit is lost quickly once the medication is no longer taken.
Why Do People Stop Taking Them?
Despite their effectiveness, discontinuation rates for GLP-1 drugs are quite high, with some studies showing that up to half of patients stop within the first year. The reasons for stopping are varied and complex. They can include gastrointestinal side effects, the high cost of the medication, supply shortages, or a belief that the drug isn't working. In other cases, a person's overall health might decline due to other illnesses, leading them or their doctor to discontinue the medication. This new research highlights that the decision to stop is not a simple one and carries potential risks that may not have been fully appreciated before.
Association vs. Causation
It is crucial to understand that the study was observational, meaning it identifies a strong association but cannot prove direct causation. In other words, researchers could not definitively say that stopping the drug itself causes the heart attacks and strokes. It's possible that the people who stopped the medication were already in poorer health for other reasons, which could contribute to both the discontinuation and the higher risk of a cardiovascular event. However, the study did note that changes in traditional risk factors like weight, blood pressure, and blood sugar after stopping were modest, suggesting these factors alone may not explain the entire increase in risk. This has led researchers to believe that losing the direct protective effects of the drug plays a significant role.
What Should Patients Do?
The key takeaway from this study is not that these drugs are dangerous, but that they are highly effective and should be taken consistently for longterm benefit. Experts stress that patients should not make any changes to their medication regimen on their own. If you are taking a GLP-1 agonist for type 2 diabetes and are considering stopping for any reason—be it side effects, cost, or something else—it is essential to have a conversation with your doctor first. Your physician can help you weigh the risks and benefits, manage any side effects, or explore alternative treatments if necessary. Abruptly stopping removes the cardiovascular shield these medications provide, and this study shows that the consequences can be swift and serious.
